Crossmark

Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry

Crossref DOI link: https://doi.org/10.1007/s10067-021-05734-3

Published Online: 2021-04-21

Published Print: 2021-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sebastiani, Marco

Venerito, Vincenzo

Bugatti, Serena

Bazzani, Chiara

Biggioggero, Martina

Petricca, Luca

Foti, Rosario

Bortoluzzi, Alessandra

Balduzzi, Silvia

Visalli, Elisa

Frediani, Bruno

Manfredi, Andreina

Gremese, Elisa

Favalli, Ennio

Iannone, Florenzo

Ferraccioli, Gianfranco

Lapadula, Giovanni

,

Galli, Elena

Cantatore, Francesco Paolo

Lomater, Claudia

Atzeni, Fabiola

Gorla, Roberto

Fusaro, Enrico

Salaffi, Fausto

Conti, Fabrizio

Cauli, Alberto

Sarzi-Puttini, Piercarlo

Carletto, Antonio

Lopalco, Giuseppe
License Information

Text and Data Mining valid from 2021-04-21

Version of Record valid from 2021-04-21
More Information

Article History

Received: 2 January 2021

Revised: 2 April 2021

Accepted: 7 April 2021

First Online: 21 April 2021

Compliance with ethical standards

:

: The study has been approved by the local ethical committees.

: None.

Document is current

Any future updates will be listed below